Compile Data Set for Download or QSAR
maximum 50k data
Found 640 with Last Name = 'renneberg' and Initial = 'd'
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241720(US9409917, 17 | US9409917, 18)
Affinity DataIC50:  1.30nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241779(US9409917, 104 | US9409917, 105 | US9409917, 76 | ...)
Affinity DataIC50:  1.30nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241725(US9409917, 22)
Affinity DataIC50:  1.5nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237018(US9388197, 20)
Affinity DataIC50:  1.5nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241720(US9409917, 17 | US9409917, 18)
Affinity DataIC50:  1.60nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237032(US9388197, 34)
Affinity DataIC50:  1.60nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237039(US9388197, 41)
Affinity DataIC50:  1.80nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241706(US9409917, 3 | US9409917, 4 | US9409917, 96 | US94...)
Affinity DataIC50:  1.80nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237060(US9388197, 62)
Affinity DataIC50:  1.90nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199025(BDBM199037 | BDBM199038 | US9221832, 89)
Affinity DataIC50:  2.20nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whol...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237065(US9388197, 67)
Affinity DataIC50:  2.60nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237063(US9388197, 65)
Affinity DataIC50:  2.70nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241727(US9409917, 24 | US9409917, 25)
Affinity DataIC50:  2.70nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241706(US9409917, 3 | US9409917, 4 | US9409917, 96 | US94...)
Affinity DataIC50:  2.70nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241743(US9409917, 40)
Affinity DataIC50:  2.70nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM274361(US95556117, Example 25,4-Chloro-7-methyl-1H-indole...)
Affinity DataIC50:  2.90nMAssay Description:The amplified sequence was subsequently ligated into a pcDNA3.1 (+) NotI, NheI digested plasmid. Human embryonic kidney (HEK) cells (ATCC CRL-1573, M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM274412(US95556117, Example 76,4-Chloro-7-methoxy-1H-indol...)
Affinity DataIC50:  2.90nMAssay Description:The amplified sequence was subsequently ligated into a pcDNA3.1 (+) NotI, NheI digested plasmid. Human embryonic kidney (HEK) cells (ATCC CRL-1573, M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241706(US9409917, 3 | US9409917, 4 | US9409917, 96 | US94...)
Affinity DataIC50:  2.90nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237025(US9388197, 27)
Affinity DataIC50:  3nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241715(US9409917, 12)
Affinity DataIC50:  3.10nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM274348(US95556117, Example 12,4-Chloro-1H-indole-5-carbox...)
Affinity DataIC50:  3.20nMAssay Description:The amplified sequence was subsequently ligated into a pcDNA3.1 (+) NotI, NheI digested plasmid. Human embryonic kidney (HEK) cells (ATCC CRL-1573, M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199025(BDBM199037 | BDBM199038 | US9221832, 89)
Affinity DataIC50:  3.20nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whol...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM274419(US95556117, Example 83,4-Chloro-7-propyl-1H-indole...)
Affinity DataIC50:  3.30nMAssay Description:The amplified sequence was subsequently ligated into a pcDNA3.1 (+) NotI, NheI digested plasmid. Human embryonic kidney (HEK) cells (ATCC CRL-1573, M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237087(US9388198, 13)
Affinity DataIC50:  3.40nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM198941(BDBM198942 | BDBM198943 | US9221832, 5)
Affinity DataIC50:  3.5nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whol...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM274418(US95556117, Example 82,4-Chloro-7-propyl-1H-indole...)
Affinity DataIC50:  3.80nMAssay Description:The amplified sequence was subsequently ligated into a pcDNA3.1 (+) NotI, NheI digested plasmid. Human embryonic kidney (HEK) cells (ATCC CRL-1573, M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237072(US9388197, 74)
Affinity DataIC50:  3.90nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM274397(US95556117, Example 61,4-Chloro-7-methyl-1H-indole...)
Affinity DataIC50:  4nMAssay Description:The amplified sequence was subsequently ligated into a pcDNA3.1 (+) NotI, NheI digested plasmid. Human embryonic kidney (HEK) cells (ATCC CRL-1573, M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM274399(US95556117, Example 63,4,7-Dimethyl-1H-indole-5-ca...)
Affinity DataIC50:  4nMAssay Description:The amplified sequence was subsequently ligated into a pcDNA3.1 (+) NotI, NheI digested plasmid. Human embryonic kidney (HEK) cells (ATCC CRL-1573, M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM274408(US95556117, Example 72,4-Chloro-7-ethyl-1H-indole-...)
Affinity DataIC50:  4.10nMAssay Description:The amplified sequence was subsequently ligated into a pcDNA3.1 (+) NotI, NheI digested plasmid. Human embryonic kidney (HEK) cells (ATCC CRL-1573, M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM274398(US95556117, Example 62,4-Chloro-7-methyl-1H-indole...)
Affinity DataIC50:  4.10nMAssay Description:The amplified sequence was subsequently ligated into a pcDNA3.1 (+) NotI, NheI digested plasmid. Human embryonic kidney (HEK) cells (ATCC CRL-1573, M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM274347(US95556117, Example 11,4-Chloro-1H-indole-5-carbox...)
Affinity DataIC50:  4.10nMAssay Description:The amplified sequence was subsequently ligated into a pcDNA3.1 (+) NotI, NheI digested plasmid. Human embryonic kidney (HEK) cells (ATCC CRL-1573, M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241782(US9409917, 79 | US9409917, 80)
Affinity DataIC50:  4.10nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237009(US9388197, 11)
Affinity DataIC50:  4.10nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM274409(US95556117, Example 73,4-Chloro-7-ethyl-1H-indole-...)
Affinity DataIC50:  4.20nMAssay Description:The amplified sequence was subsequently ligated into a pcDNA3.1 (+) NotI, NheI digested plasmid. Human embryonic kidney (HEK) cells (ATCC CRL-1573, M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237058(US9388197, 60)
Affinity DataIC50:  4.30nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237066(US9388197, 68)
Affinity DataIC50:  4.30nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237004(US9388197, 6)
Affinity DataIC50:  4.30nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM274389(US95556117, Example 53,4-Chloro-7-(3-methoxy-propy...)
Affinity DataIC50:  4.40nMAssay Description:The amplified sequence was subsequently ligated into a pcDNA3.1 (+) NotI, NheI digested plasmid. Human embryonic kidney (HEK) cells (ATCC CRL-1573, M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM274350(US95556117, Example 14,4-Chloro-1H-indole-5-carbox...)
Affinity DataIC50:  4.5nMAssay Description:The amplified sequence was subsequently ligated into a pcDNA3.1 (+) NotI, NheI digested plasmid. Human embryonic kidney (HEK) cells (ATCC CRL-1573, M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237017(US9388197, 19)
Affinity DataIC50:  4.5nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199023(US9221832, 87)
Affinity DataIC50:  4.60nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whol...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM274360(US95556117, Example 24,4-Chloro-7-methyl-1H-indole...)
Affinity DataIC50:  4.70nMAssay Description:The amplified sequence was subsequently ligated into a pcDNA3.1 (+) NotI, NheI digested plasmid. Human embryonic kidney (HEK) cells (ATCC CRL-1573, M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237026(US9388197, 28)
Affinity DataIC50:  4.70nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM274403(US95556117, Example 67,rac-4-Chloro-7-(1-hydroxy-e...)
Affinity DataIC50:  4.70nMAssay Description:The amplified sequence was subsequently ligated into a pcDNA3.1 (+) NotI, NheI digested plasmid. Human embryonic kidney (HEK) cells (ATCC CRL-1573, M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM198970(BDBM199009 | BDBM199010 | US9221832, 34)
Affinity DataIC50:  4.70nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whol...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241779(US9409917, 104 | US9409917, 105 | US9409917, 76 | ...)
Affinity DataIC50:  4.70nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241714(US9409917, 11)
Affinity DataIC50:  4.80nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237057(US9388197, 59)
Affinity DataIC50:  4.90nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProstaglandin D2 receptor 2(Homo sapiens (Human))
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50435091(CHEMBL2391524)
Affinity DataIC50:  5nMAssay Description:Displacement of [3H]PGD2 from human CRTh2 receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Displayed 1 to 50 (of 640 total ) | Next | Last >>
Jump to: